Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pCMFlag_hsGATA2 (#RDB07004)

Expression vector of human GATA2.

Alternative name SET-0121_4
Clone info. Expression vector of human GATA2. Expression has not yet been confirmed.
Comment cDNA fragment 338 to 1,777 of NM_032638.4 is cloned. PCR cloning, forward primer: gaggtggcgccggagcagcc; reverse primer: ctagcccatggcggtcaccatg. Known difference: C to G substitution at 349 nt (synonymous).
Vector backbone pCMV_S-FLAG (RDB05956) (Plasmid)
Size of vector backbone 5.5 kb
Selectable markers Amp^r (E. coli), Neo^r (mammalian cell)
Growth conditions 37C, LB+Amp
Gene/insert name Human GATA2 cDNA
Depositor|Developer DNA Bank, |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
MTA, for use for for-profit purpose [Word]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution The RECIPIENT agrees to describe RIKEN BRC as the source of the MATERIAL in any publication.
Additional terms and conditions:
Regrding pRc/CMV:
a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only.
b) LIFE MATERIALS shall not be used for any commercial purposes.
c) LIFE MATERIALS shall not be transferred beyond the specified recipient.
d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
提供同意書 (MTA, 営利目的用)[Word]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 発表に際し、理研BRCから入手したことを明記すること。
付加的使用条件:
pRc/CMVについて:
a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only.
b) LIFE MATERIALS shall not be used for any commercial purposes.
c) LIFE MATERIALS shall not be transferred beyond the specified recipient.
d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above.

Catalog # Resource name Shipping form Fee
RDB07004 pCMFlag_hsGATA2 DNA solution JPY 9,460 (not-for-profit academic purpose)
JPY 18,920 (for-profit-research purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pCMFlag_hsGATA2 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07004).

Reference section:

Further references such as user reports and related articles (go to bottom)


QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB13716_A5L4p1.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: SV40pro_F
Sequence file: RDB13716_A5L4a.seq check
>07004_13716_A5L4_CMV-Forward_E09_15.ab1
    1 CTTTAAACTT CCGCCCAATT GACGCAATGG GCGGTAGGCG TGTACGGTGG GAGGTCTATA
   61 TAAGCAGAGC TCTCTGGCTA ACTAGAGAAC CCACTGCTTA CTGGCTTATC GAAATTAATA
  121 CGACTCACTA TAGGGAGACC CAAGCTGAAT TCACCATGGA CTACAAGGAC GATGACGATA
  181 AGGCGGCCGA GGTGGCGCCG GAGCAGCCGC GCTGGATGGC GCACCCGGCC GTGCTGAATG
  241 CGCAGCACCC CGACTCACAC CACCCGGGCC TGGCGCACAA CTACATGGAA CCCGCGCAGC
  301 TGCTGCCTCC AGACGAGGTG GACGTCTTCT TCAATCACCT CGACTCGCAG GGCAACCCCT
  361 ACTATGCCAA CCCCGCTCAC GCGCGGGCGC GCGTCTCCTA CAGCCCCGCG CACGCCCGCC
  421 TGACCGGAGG CCAGATGTGC CGCCCACACT TGTTGCACAG CCCGGGTTTG CCCTGGCTGG
  481 ACGGGGGCAA AGCAGCCCTC TCTGCCGCTG CGGCCCACCA CCACAACCCC TGGACCGTGA
  541 GCCCCTTCTC CAAGACGCCA CTGCACCCCT CAGCTGCTGG AGGCCCTGGA GGCCCACTCT
  601 CTGTGTACCC AGGGGCTGGG GGTGGGAGCG GGGGAGGCAG CGGGAGCTCA GTGGCCTCCC
  661 TCACCCCTAC AGCAGCCCAC TCTGGCTCCC ACCTTTTCGG CTTCCCACCC ACGCCACCCA
  721 AAGAAGTGTC TCCTGACCCT AGCACCACGG GGGCTGCGTC TCCAGCCTCA TCTTCCGCGG
  781 GGGGTAGTGC AGCCCGAGGA GAGGACAAGG ACGGCGTCAA GTACCAGGTG TCACTGACGG
  841 AGAGCATGAA GATGGAAAGT GGCAGTCCCC TGCGCCCAGG CCTAGCTACT ATGGGCACCC
  901 AGCCTGCTAC ACACCACCCC CATCCCCACC TACCCCTCCT ATGTGCCGGC GGCTGCCCAC
  961 GACTACAGCA GCGGACTCTT TCCACCCCGG GAGGCTTCCT GGGGGGGGAC CGGGCCTCCA
 1021 GCTTTCACCC CCTAAGGCAG CGCAGCAAAG GCTCGTTTCC CTGTTTCAGA GGCCGGGAGG
 1081 TTGTTGTTCA ACTGTGAGGC TACAGGCCAC CCTCTCTGGG CGGTGGGGAA CGGGCACCCA
1141 G
//
Primer: SV40 pro,Zeo,SV40p(A)
Sequence file: RDB13716_A5L4b.seq check
>07004_13716_A5L4_BGHrev_F09_18.ab1
    1 GAACGGGCAT TTTAGGGTGA ACTATAAGAA TAGGGCCCTC TAGATGCATG CTCGAGCGGC
   61 CCTAGCCCAT GGCGGTCACC ATGCTGGACG GGTGGGGGTG GCCGAAGGAG AGGCTGGAGG
  121 AGGGGTGGAT GGGCGTCGGA GTGGGCAGGA TGTGTCCGGA GTGGCTGAAG GGCGGGAGGT
  181 GGCCCACAGG TGCCATGTGT CCAGCCAGGG CAGCTGCACT GAAGGGGGAT GACTTCTCCT
  241 GCATGCACTT TGACAGCTCC TCGAAGCACT CCGCCCCTTT CTTGCTCTTC TTGGACTTGT
  301 TGGACATCTT CCGGTTCCGA GTCTGGATCC CTTCCTTCTT CATGGTCAGT GGCCTGTTAA
  361 CATTGTGCAG CTTGTAGTAG AGGCCACAGG CGTTGCAGAC AGGGTCCCCG TTGGCGTTTC
  421 GGCGCCATAA GGTGGTGGTT GTCGTCTGAC AATTTGCACA ACAGGTGCCG GCTCTTCTGG
  481 CGGCCGACAG TCTTCGCTTG GGCTTGATGA GTGGTCGGTT CTGCCCATTC ATCTTGTGGT
  541 AGAGGCCACA GGCATTGCAC AGGTAGTGGC CGGTGCCGTC CCGCCGCCAG AGAGGGGTGG
  601 CTGTGGCCCC ACAGTTGACA CACTCCCGGC CTTCTGAACA GGAACGAGCC TTGCTGCGCT
  661 GCTTAGGGGT GAAGCTGGAG GCCGGTCCCC CCAGGAAGCC TCCGGGGTGG AAGAGTCCGC
721 TGCTGTAGTC GTGGGCAGCC GCCGGCACAT AGGAGGGGTA GGTGGGGATG GGGTGGTGT
//
Primer: SV40pro_F_V2
Sequence file: RDB13716_A5L4c.seq check
>07004_13716_A5L4_SV40pro_F_V2_G09_21.ab1
    1 TCACAACTTT TTGGGAGGCC TAGGCTTTTG CAAAAGCTCC CGGGAGCTTG GATATCCATT
   61 TTCGGATCTG ATCAAGAGAC AGGATGAGGA TCGTTTCGCA TGATTGAACA AGATGGATTG
  121 CACGCAGGTT CTCCGGCCGC TTGGGTGGAG AGGCTATTCG GCTATGACTG GGCACAACAG
  181 ACAATCGGCT GCTCTGATGC CGCCGTGTTC CGGCTGTCAG CGCAGGGGCG CCCGGTTCTT
  241 TTTGTCAAGA CCGACCTGTC CGGTGCCCTG AATGAACTGC AGGACGAGGC AGCGCGGCTA
  301 TCGTGGCTGG CCACGACGGG CGTTCCTTGC GCAGCTGTGC TCGACGTTGT CACTGAAGCG
  361 GGAAGGGACT GGCTGCTATT GGGCGAAGTG CCGGGGCAGG ATCTCCTGTC ATCTCACCTT
  421 GCTCCTGCCG AGAAAGTATC CATCATGGCT GATGCAATGC GGCGGCTGCA TACGCTTGAT
  481 CCGGCTACCT GCCCATTCGA CCACCAAGCG AAACATCGCA TCGAGCGAGC ACGTACTCGG
  541 ATGGAAGCCG GTCTTGTCGA TCAGGATGAT CTGGACGAAG AGCATCAGGG GCTCGCGCCA
  601 GCCGAACTGT TCGCCAGGCT CAAGGCGCGC ATGCCCGACG GCGAGGATCT CGTCGTGACC
  661 CATGGCGATG CCTGCTTGCC GAATATCATG GTGGAAAATG GCCGCTTTTC TGGATTCATC
  721 GACTGTGGCC GGCTGGGTGT GGCGGACCGC TATCAGGACA TAGCGTTGGC TACCCGTGAT
  781 ATTGCTGAAG AGCTTGGCGG CGAATGGGCT GACCGCTTCC TCGTGCTTTA CGGTATCGCC
  841 GCTCCCGATT CGCAGCGCAT CGCCTTCTAT CGCCTTCTTG ACGAGTTCTT CTGAGCGGGA
  901 CTCTGGGGTT CGAAATGACC GACCAAGCGA CGCCCAACCT GCCATCACGA GATTTCGATT
  961 CCACCGCCCG CCCTTCTATG AAGGGTTGGG GCTTTCGGAA ATCGTTTTTC CCGGGACGCC
 1021 GGCTGGATGA TCCTCCAGCG CGGGGATCTC ATGCTGGAGT TCTTCGCCAA CCCCACTTGT
1081 TTATTGCAGC CTATATGCTA CCAATAAGGC ATTAGGCATC AACGAAATTT CACACA
//

Please visit Sequencing and PCR primers for primer information.


References

Original, user report and related articles